Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells by elevated ROS production

Cancer Letters

Volumn 382, Issue 2, 2016, Pages 157-165

  Seol, Hyang Sook ^a   Lee, Sang Eun ^a   Song, Joon Seon ^a   Lee, Hye Yong ^a   Park, Sojung ^a   Kim, Inki ^a   Singh, Shree Ram ^b   Chang, Suhwan ^a   Jang, Se Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Drug repositioning; Hepatocellular carcinoma; Riluzole; ROS

Indexed keywords

CASPASE 3; CASPASE 9; GLUTAMIC ACID; GLUTATHIONE; REACTIVE OXYGEN METABOLITE; RILUZOLE; SORAFENIB; AMINO ACID RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; CELL CYCLE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CARCINOMA CELL LINE; CONTROLLED STUDY; DRUG MECHANISM; DRUG REPOSITIONING; G2 PHASE CELL CYCLE CHECKPOINT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; LIVER NEOPLASMS; METABOLISM; NONOBESE DIABETIC MOUSE; NUDE MOUSE; OXIDATIVE STRESS; PATHOLOGY; SCID MOUSE; TUMOR CELL CULTURE; TUMOR CELL LINE; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG REPOSITIONING; EXCITATORY AMINO ACID ANTAGONISTS; G2 PHASE CELL CYCLE CHECKPOINTS; GLUTAMIC ACID; GLUTATHIONE; HUMANS; LIVER NEOPLASMS; MALE; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RILUZOLE; SIGNAL TRANSDUCTION; TUMOR BURDEN; TUMOR CELLS, CULTURED; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84987827808     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.08.028     Document Type: Article

References (19)

1. [1] Llovet, J.M., Burroughs, A., Bruix, J., Hepatocellular carcinoma. Lancet 362 (2003), 1907–1917.
2. [2] Wilhelm, S.M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004), 7099–7109.
3. [3] Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66 (2006), 11851–11858.
4. [4] Abou-Alfa, G.K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol 24 (2006), 4293–4300.
5. [5] Strumberg, D., Clark, J.W., Awada, A., Moore, M.J., Richly, H., Hendlisz, A., et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12 (2007), 426–437.
6. [6] Batchelor, T.T., Sorensen, A.G., di Tomaso, E., Zhang, W.T., Duda, D.G., Cohen, K.S., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007), 83–95.
7. [7] Makarova, A.S., Lazarevich, N.L., Deregulation of signaling pathways involved in sorafenib resistance of hepatocellular carcinoma. Klin. Lab. Diagn 66–68 (2013), 34–67.
8. [8] Mancuso, M.R., Davis, R., Norberg, S.M., O'Brien, S., Sennino, B., Nakahara, T., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest 116 (2006), 2610–2621.
9. [9] DeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G., Thompson, C.B., The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7 (2008), 11–20.
10. [10] Peck-Radosavljevic, M., Drug therapy for advanced-stage liver cancer. Liver Cancer 3 (2014), 125–131.
11. [11] Seol, H.S., Lee, S.E., Song, J.S., Rhee, J.K., Singh, S.R., Chang, S., et al. Complement proteins C7 and CFH control the stemness of liver cancer cells via LSF-1. Cancer Lett 372 (2016), 24–35.
12. [12] Le, M.N., Chan, J.L., Rosenberg, S.A., Nabatian, A.S., Merrigan, K.T., Cohen-Solal, K.A., et al. The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells. J. Invest. Dermatol 130 (2010), 2240–2249.
13. [13] Deng, Y., Xu, Z.F., Liu, W., Xu, B., Yang, H.B., Wei, Y.G., Riluzole-triggered GSH synthesis via activation of glutamate transporters to antagonize methylmercury-induced oxidative stress in rat cerebral cortex. Oxid. Med. Cell. Longev, 2012, 2012, 534705.
14. [14] Herner, A., Sauliunaite, D., Michalski, C.W., Erkan, M., De Oliveira, T., Abiatari, I., et al. Glutamate increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Kras-MAPK signaling. Int. J. Cancer 129 (2011), 2349–2359.
15. [15] Hu, H., Takano, N., Xiang, L., Gilkes, D.M., Luo, W., Semenza, G.L., Hypoxia-inducible factors enhance glutamate signaling in cancer cells. Oncotarget 5 (2014), 8853–8868.
16. [16] Willard, S.S., Koochekpour, S., Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications. Int. J. Biol. Sci 9 (2013), 728–742.
17. [17] Doble, A., The pharmacology and mechanism of action of riluzole. Neurology 47 (1996), S233–S241.
18. [18] Pozo-Molina, G., Ponciano-Gomez, A., Rivera-Gonzalez, G.C., Hernandez-Zavala, A., Garrido, E., Arsenic-induced S phase cell cycle lengthening is associated with ROS generation, p53 signaling and CDC25A expression. Chem. Biol. Interact 238 (2015), 170–179.
19. [19] Li, L., Zheng, B.B., Ma, L.S., Sun, X., Chang, J.J., Xie, W.D., et al. Telekin suppresses human hepatocellular carcinoma cells in vitro by inducing G2/M phase arrest via the p38 MAPK signaling pathway. Acta Pharmacol. Sin 35 (2014), 1311–1322.